Editorial: Influenza Virus Vaccines and Immunotherapies by Arun Kumar & Shakti Singh
EDITORIAL
published: 24 November 2015
doi: 10.3389/fimmu.2015.00599
Edited and reviewed by:
Laurent Rénia,
Agency for Science, Research and
Technology, Singapore
*Correspondence:
Arun Kumar
arun.q.kumar@gsk.com;
Shakti Singh
shakti.singh@ualberta.ca
†Arun Kumar and Shakti Singh have
contributed equally to this work.
Specialty section:
This article was submitted to
Immunotherapies and Vaccines,
a section of the journal
Frontiers in Immunology
Received: 27 October 2015
Accepted: 09 November 2015
Published: 24 November 2015
Citation:
Kumar A and Singh S (2015) Editorial:
Influenza Virus Vaccines and
Immunotherapies.
Front. Immunol. 6:599.
doi: 10.3389/fimmu.2015.00599
Editorial: Influenza Virus Vaccines
and Immunotherapies
Arun Kumar 1*† and Shakti Singh2*†
1 GlaxoSmithKline Vaccines, Research Center, Siena, Italy, 2 Department of Surgery, University of Alberta, Edmonton, AB,
Canada
Keywords: influenza, human, influenza A virus, vaccines, influenza vaccines, immunotherapy
Influenza virus infections are responsible for billions of dollars of economic burden annually
worldwide. Regardless of advances in our understanding of the immune evasion mechanism,
the disease remains one of the foremost threats for human being (1). Currently available vac-
cines and therapeutic agents are not very potent against the deadly flu infections because of the
frequent mutations in influenza virus subtypes. The mismatch between the circulating strains
and vaccine strains critically affects the success rate of the conventional vaccines and requires
continuous monitoring of circulating influenza strains. These collective limitations of existing flu
vaccines urgently call for the development of novel vaccines with a wide range of cross-protective
immunity (2). The discovery and development of new and improved vaccines have been greatly
facilitated by the application of new technologies. The articles included in this research topic
explain the key methods of improvement in existing vaccines, therapeutics, and mechanism of
protection.
The opening articles of the present topic discuss about the novel methods of improving existing
influenza vaccines and enhancing immune responses. Various strategies including use of adjuvants,
heterologous prime/boost and unique antigen design have shown to induce protective influenza-
specific neutralizing antibodies. Lofano et al. reviewed recent advancements in the flu vaccine
development and highlight the role of B-cells in controlling influenza virus infections (3). Soema
et al. discussed the recent developments and design of T-cell based vaccines based on novel
peptide and protein-based vaccine formulations (4). Adjuvants play a critical role in the induction
of rapid, effective, and durable immune responses when administered with vaccine antigens.
Recent progress in the adjuvant formulations allows existing vaccines to reduce the number of
booster doses, increase dose-sparing ability, induce potent T and B-cell responses and enhance
breadth of the immune responses against heterotypic antigens (5). Vogel and Brown reported
that only single dose of CpG adjuvanted influenza vaccine can induce robust memory T-cell
responses and confer protection against heterosubtypic challenge (6). Similarly, in the presence
of oil-in-water emulsion adjuvant system (AS03), even a very small dose of influenza vaccine can
induce significantly strong immune responses (7). Alternative strategies of immune protection
such as use of immuno-modulatory agents like TLR agonist can activate protective non-specific
antiviral immune responses. Mifsud et al. demonstrated that mice pre-treated with TLR-2 ago-
nist PEG-Pam2Cys were able to mount specific B- and T-cell responses and also protect mice
against heterologous virus challenge (8). These types of alternative strategies can provide imme-
diate immune protection in the absence of effective vaccine without compromising the antiviral
specific immunity.
The next generation universal influenza vaccine targets the most conserved structure of the virus
and hence confers heterotypic protection, for example, new vaccine strategies target stalk of the
HA instead of the globular head. Mallajosyula et al. designed a potent immunogen comprised of
HA-stem-fragment from H3N2 strain (A/Hong Kong/1/68) and trimerization motifs: coiled-coil
isoleucine zipper and globular β-rich. Immunization of mice with the immunogen induced cross-
reactive antibodies and provided only partial protection against homologous virus challenge (9).
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Li et al. engineered a dual vaccine by incorporating botulinum
neurotoxin A (BoNT/A) receptor-binding subdomain in univer-
sal influenza vector based on PR8 strain of influenza virus. This
vaccine induced protective immunity against both BoNT/A and
Influenza virus. Potent immune responses can also be generated
by exploiting receptors on antigen presenting cells (APCs) (10).
Grodeland et al. demonstrated that a novel DNA vaccine can-
didate specifically induced Th2 and IgG1 antibody responses or
Th1 and IgG2a responses by targeting hemagglutinin to MHC
class II molecules or chemokine receptors (XCR1 or CCR1/3/5),
respectively (11).
The historical 1918 influenza pandemic caused very high mor-
tality in adult population and the immunological parameters
in this population still remain speculative. In light of current
understanding of influenza immuno-pathogenesis, McAuley et al.
claimed that, the highmortality rate in the adult population is due
to the dysfunctional or excessive cross-reactive memory T-cells,
induced by previous influenza infections, which render these indi-
vidual susceptible to the 1918 pandemic influenza (12). Peng et al.
provided the evidence that pre-existing seasonal influenza virus
HA-specific cross-reactive T-cells can be boosted by a heterol-
ogous vaccine (13). Pregnant women are at paramount priority
for influenza vaccination due to influenza virus related compli-
cations during the pregnancy. Modulation of maternal immunity
during the pregnancy can influence the influenza vaccine specific
immune responses. Kay andBlish summarize the immunogenicity
and efficacy of the influenza vaccine and discuss impact on T and
B-cell responses during the pregnancy (14).
Apart from prophylactic vaccine, therapeutic approaches also
required for those severely infected with the influenza virus. The
use of antibodies seems to be an attractive immunotherapeutic
approach for the treatment of various infectious diseases.
Sasisekharan et al. reviewed different antibody based strategies
to prevent and treat the influenza infections (15). The cells of
innate immune system are triggered by signaling pathways during
influenza virus infection that causes extensive damage to lung
tissues and in airway lining, resulting in severe immunopathology.
Ramos and Sesma suggest that these damages can be minimized
by selectively modulating the innate signaling pathways using
immuno-modulatory drugs while maintaining the ability of the
host cells to mount an antiviral response to control virus repli-
cation (16). Further, Graham et al. described the role of mast
cells in immunopathology during influenza A virus infection and
suggested them as a potential drug target in viral infections (17).
The new strategies for vaccine design also require more sen-
sitive and efficient methods for the evaluation of the vaccine
potency. Carnell et al. reviewed comprehensive methods for
influenza virus neutralization assays, based on the pseudotype
viral particles, which utilize chimeric viruses bearing influenza
glycoproteins, and depict how such assays can replace the tra-
ditional HA neutralization assays for the evaluation of new age
influenza vaccines (18). To detect the incidence of Influenza virus
with high efficiency and accuracy, Rajput et al. generated HA
specific high affinity recombinant single chain variable fragment
(scFv) antibodies showing high sensitivity (83.9%) and specificity
(100%) for three different strains of influenza virus (19).
The compilation of research articles included in this research
topic should help reader to have an overview of different strategies
for improving existing influenza vaccines and immunotherapies.
This research topic also highlights the progress made in under-
standing of the immune protection and pathogenic mechanisms
of influenza virus.
REFERENCES
1. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med (2010)
363:2036–44. doi:10.1056/NEJMra1002842
2. Schwartzman LM, Cathcart AL, Pujanauski LM, Qi L, Kash JC, Taubenberger
JK.An intranasal virus-like particle vaccine broadly protectsmice frommultiple
subtypes of influenza A virus. MBIO (2015) 6(4):e01044. doi:10.1128/mBio.
01044-15
3. Lofano G, Kumar A, Finco O, Del Giudice G, Bertholet S. B cells and functional
antibody responses to combat influenza. Front Immunol (2015) 6:336. doi:10.
3389/fimmu.2015.00336
4. Soema PC, van Riet E, Kersten G, Amorij J-P. Development of cross-protective
influenza A vaccines based on cellular responses. Front Immunol (2015) 6:237.
doi:10.3389/fimmu.2015.00237
5. Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza
vaccines. Expert Rev Vaccines (2013) 12:1095–108. doi:10.1586/14760584.2013.
825445
6. Vogel A, BrownD. Single dose CpG immunization protects against a heterosub-
typic challenge and generates antigen specific memory T cells. Front Immunol
(2015) 6:327. doi:10.3389/fimmu.2015.00327
7. Yam KK, Gupta J, Winter K, Allen E, Brewer A, Beaulieu É, et al. AS03-
adjuvanted, very-low-dose influenza vaccines induce distinctive immune
responses compared to unadjuvanted high-dose vaccines in BALB/cmice. Front
Immunol (2015) 6:207. doi:10.3389/fimmu.2015.00207
8. Mifsud EJ, Tan AC-L, Brown LE, Chua BYL, Jackson DC. Generation of adap-
tive immune responses following influenza virus challenge is not compromised
by pre-treatmentwith theTLR-2 agonist Pam2Cys.Front Immunol (2015) 6:290.
doi:10.3389/fimmu.2015.00290
9. Mallajosyula VA, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA, et al.
Hemagglutinin sequence conservation guided stem immunogen design from
influenza AH3 subtype. Front Immunol (2015) 6:329. doi:10.3389/fimmu.2015.
00329
10. Li J, Diaz-Arévalo D, Chen Y, Zeng M. Intranasal vaccination with an engi-
neered influenza virus expressing the receptor binding subdomain of botulinum
neurotoxin provides protective immunity against botulism and influenza. Front
Immunol (2015) 6:170. doi:10.3389/fimmu.2015.00170
11. Grodeland G, Fossum E, Bogen B. Polarizing T and B cell responses by APC-
targeted subunit vaccines. Front Immunol (2015) 6:367. doi:10.3389/fimmu.
2015.00367
12. McAuley J, Kedzierska K, Brown L, Shanks D. Host immunological factors
enhancingmortality of young adults during the 1918 influenza pandemic. Front
Immunol (2015) 6:419. doi:10.3389/fimmu.2015.00419
13. Peng Y,Wang B, Talaat K, Karron R, Powell TJ, ZengH, et al. Boosted influenza-
specific T cell responses after H5N1 pandemic live attenuated influenza virus
(pLAIV) vaccination. Front Immunol (2015) 6:287. doi:10.3389/fimmu.2015.
00287
14. Kay AW, Blish CA. Immunogenicity and clinical efficacy of influenza
vaccination in pregnancy. Front Immunol (2015) 6:289. doi:10.3389/fimmu.
2015.00289
15. Sasisekharan R, Shriver Z. Antibody-based strategies to prevent and
treat influenza. Front Immunol (2015) 6:315. doi:10.3389/fimmu.2015.
00315
16. Ramos I, Fernandez-Sesma A. Modulating the innate immune
response to influenza A virus: potential therapeutic use of anti-
inflammatory drugs. Front Immunol (2015) 6:361. doi:10.3389/fimmu.2015.
00361
Frontiers in Immunology | www.frontiersin.org November 2015 | Volume 6 | Article 5992
Kumar and Singh Influenza Virus Vaccines
17. GrahamAC, Temple RM, Obar JJ. Mast cells and influenza A virus: Association
with allergic responses and beyond. Front Immunol (2015) 6:238. doi:10.3389/
fimmu.2015.00238
18. Carnell GW, Ferrara F, Grehan K, Thompson CP, Temperton NJ. Pseudotype-
based neutralization assays for influenza: a systematic analysis. Front Immunol
(2015) 6:161. doi:10.3389/fimmu.2015.00161
19. Rajput R, Sharma G, Rawat V, Gautam A, Kumar B, Pattnaik B, et al. Diagnos-
tic potential of recombinant scFv antibodies generated against hemagglutinin
protein of influenza A virus. Front Immunol (2015) 6:440. doi:10.3389/fimmu.
2015.00440
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Kumar and Singh. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or
licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org November 2015 | Volume 6 | Article 5993
